Health Care • Biotechnology: Pharmaceutical Preparations
$1.75 ▼ -0.11
(-5.91%)
MKT CAP: $92.7M • VOL: 32.6K
52W L $2 52W H $49
ROARABLE / RQD
E • 31/100
PIOTROSKI
3 / 9
PLYX // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 |
|---|---|---|
| Revenue (Total Sales) | $0 | $0 |
| YoY Revenue Growth % | — | — |
| Gross Profit | — | — |
| Gross Margin % | — | — |
| Research & Development (R&D) | — | — |
| Operating Income (EBIT) | -$7.8M | -$4.4M |
| Operating Margin % | — | — |
| Net Income (GAAP) | -$9.0M | -$30.4M |
| EBITDA (Normalized) | — | — |
| Diluted EPS ($/sh) | — | — |
| Operating Cash Flow (OCF) | -$3.9M | -$2.6M |
| Capital Expenditures (CapEx) | — | — |
| Free Cash Flow (FCF) | -$3.9M | -$2.6M |
| FCF Margin % | — | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% |
| Cash & Short-Term Equivalents | $5.1M | $4.6M |
| Total Debt (Short + Long Term) | — | — |
| Total Stockholders' Equity | $4.6M | $4.7M |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR PLYX.